PulseCare, a Shenzhen-based maker of minimally and non-invasive treatment devices, has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. The round was led by Kangju Venture Capital and Tsinghua Innovation Ventures. The proceeds will be directed towards clinical studies and the development of new product layouts, further expanding PulseCare’s innovative device portfolio.
Company Background and Product Pipeline
Founded in 2021, PulseCare is at the forefront of developing novel therapeutic devices targeting cardiac electrophysiology (atrial fibrillation), liver tumors, and intractable hypertension. Among its product pipelines is the world’s first third-generation nanosecond pulsed electric field ablation (nsPFA) atrial fibrillation treatment product. This groundbreaking device concluded its first clinical study in November 2022 and is currently recruiting for a multi-center clinical study in China. Additionally, PulseCare’s multimodal pulsed electric field tumor ablation product, claimed to be the world’s first of its kind, has initiated a regulatory clinical study. Both products have been filed for breakthrough device designations in China and the United States, highlighting their potential to revolutionize treatment protocols in their respective fields.
Investment and Future Prospects
The Pre-Series A financing round led by Kangju Venture Capital and Tsinghua Innovation Ventures underscores the confidence of investors in PulseCare’s innovative approach and the market potential of its devices. With the funds secured, PulseCare is well-positioned to accelerate its clinical studies and bring its minimally invasive treatment solutions to market, addressing significant unmet needs in the medical device sector.-Fineline Info & Tech
